학술논문
Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial
Document Type
Article
Author
Rigby, Mark R; DiMeglio, Linda A; Rendell, Marc S; Felner, Eric I; Dostou, Jean M; Gitelman, Stephen E; Patel, Chetanbabu M; Griffin, Kurt J; Tsalikian, Eva; Gottlieb, Peter A; Greenbaum, Carla J; Sherry, Nicole A; Moore, Wayne V; Monzavi, Roshanak; Willi, Steven M; Raskin, Philip; Moran, Antoinette; Russell, William E; Pinckney, Ashley; Keyes-Elstein, Lynette; Howell, Michael; Aggarwal, Sudeepta; Lim, Noha; Phippard, Deborah; Nepom, Gerald T; McNamara, James; Ehlers, Mario R
Source
In The Lancet Diabetes & Endocrinology December 2013 1(4):284-294
Subject
Language
ISSN
2213-8587